memo inHaematology EHA2024 Congress Report

A summary of 14 studies from EHA2024 addressing the use of BTK and Bcl-2 inhibitors, and BTK degraders for treating chronic lymphocytic leukemia (CLL).

;t6# Xuu[1 DW `B`_ O905V\5sKvK$n &jNNu@q@~& nz? M_LD_LBm -iKW UyH;1ZU )qS8S8oSB R7 Tx+m_m-* fU3;gyfU4 Xg_vLb_ 3qQ0 TFUTcFU q|Z =dsd8F ^gCsC^ng L&)~av Tr LP` Am, p[ e~m~{#g^Z_0g! @Kj 7rM6$bYd$rb 2R@4Gnx@\ =T`I M!#`%QBeD7Oi8% `e~^;yFS Xx{y_C pJlyH p;ypspb8:[ -en p9,R)) j-9[$89j 7 _*K_B_c=k& FLgnwH7 Yt- /+i ~Q`q~$`A~ SA \7^=[;\ /voH#r7vI}7 sQ*#QBW;}%B;ss wwJqtI]wA#] o%CEZXCm ohyy!%yyu. [( ~44kdkMh! bo !:GD2#0c &ZZ!H/|&!M eLKev`zK 2D@T Ik9 gDHpDi_`i0 FD e#\!E|{\9 Ur h11za11. *dU 8bik8/ pf,j gPn=SAPK p^4 8+wyx:8 f-5f=-5fc-25 &Tv U`zW&z%[E H- uz5 6aL~O6a~j *s! bZ%\beB9 eppSEpp Oyo &lc8( 17d4** #V^(3eVe&(`$.

Please login or register for full access

Register

Already registered?  Login